Niagen Bioscience Inc(NAGE)Earnings, Financials & Key Ratios
NAGE•NASDAQ
$4.19
$336M mkt cap·21.0× P/E·Price updated May 7, 2026
AboutNiagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.Show more
- Revenue$129M+29.9%
- EBITDA$16M+71.0%
- Net Income$17M+103.3%
- EPS (Diluted)0.20+81.8%
- Gross Margin64.28%+3.9%
- EBITDA Margin12.17%+31.6%
- Operating Margin11.05%+42.4%
- Net Margin13.43%+56.4%
- ROE28.35%+23.6%
- ROIC114.07%-13.4%
- Debt/Equity0.04-36.0%
NAGE Key Insights
Niagen Bioscience Inc (NAGE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 16.9%
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NAGE Price & Volume
Niagen Bioscience Inc (NAGE) stock price & volume — 10-year historical chart
Loading chart...
NAGE Growth Metrics
Niagen Bioscience Inc (NAGE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.89%
5 Years16.91%
3 Years21.56%
TTM29.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM103.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM94.02%
Return on Capital
10 Years-47.47%
5 Years-22.53%
3 Years7.76%
Last Year20.9%
NAGE Recent Earnings
Niagen Bioscience Inc (NAGE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026EPS
$0.07
Est $0.06
+16.7%
Revenue
$31M
Est $31M
+1.7%
Q2 2026
Mar 4, 2026EPS
$0.03
Est $0.02
+50.0%
Revenue
$34M
Est $32M
+6.7%
Q4 2025
Nov 4, 2025EPS
$0.05
Est $0.01
+233.3%
Revenue
$34M
Est $31M
+9.3%
Q3 2025
Aug 6, 2025EPS
$0.04
Est $0.02
+100.0%
Revenue
$31M
Est $31M
+1.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.07vs $0.06+16.7% | $31Mvs $31M+1.7% |
| Q2 2026 | Mar 4, 2026 | $0.03vs $0.02+50.0% | $34Mvs $32M+6.7% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.01+233.3% | $34Mvs $31M+9.3% |
| Q3 2025 | Aug 6, 2025 | $0.04vs $0.02+100.0% | $31Mvs $31M+1.2% |
Based on last 12 quarters of dataView full earnings history →
NAGE Peer Comparison
Niagen Bioscience Inc (NAGE) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% | ||||
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 NBIX | 15.01B | 149.59 | 32.03 | 21.45% | 21.55% | 21.64% | 0.13 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 AMGN | 177.59B | 329.06 | 23.12 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare NAGE vs Peers
Niagen Bioscience Inc (NAGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NAGE Income Statement
Niagen Bioscience Inc (NAGE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 21.2M | 31.56M | 46.29M | 59.26M | 67.45M | 72.05M | 83.57M | 99.6M | 129.42M |
| Revenue Growth % | -2.14% | 48.85% | 46.69% | 28.01% | 13.82% | 6.82% | 15.99% | 19.18% | 29.95% |
| Cost of Goods Sold | 10.72M | 15.5M | 20.52M | 23.98M | 25.96M | 29.25M | 32.79M | 38.01M | 46.23M |
| COGS % of Revenue | 50.58% | 49.12% | 44.33% | 40.47% | 38.49% | 40.6% | 39.24% | 38.16% | 35.72% |
| Gross Profit | 10.48M▲ 0% | 16.05M▲ 53.2% | 25.77M▲ 60.5% | 35.27M▲ 36.9% | 41.49M▲ 17.6% | 42.8M▲ 3.2% | 50.78M▲ 18.7% | 61.59M▲ 21.3% | 83.19M▲ 35.1% |
| Gross Margin % | 49.42% | 50.88% | 55.67% | 59.53% | 61.51% | 59.4% | 60.76% | 61.84% | 64.28% |
| Gross Profit Growth % | 0.83% | 53.24% | 60.5% | 36.89% | 17.62% | 3.15% | 18.65% | 21.28% | 35.08% |
| Operating Expenses | 26.85M | 49.23M | 57.07M | 55.13M | 68.56M | 61.42M | 56.38M | 53.86M | 68.89M |
| OpEx % of Revenue | 126.66% | 155.99% | 123.28% | 93.03% | 101.65% | 85.25% | 67.46% | 54.08% | 53.23% |
| Selling, General & Admin | 22.1M | 43.67M | 52.52M | 51.71M | 64.73M | 56.6M | 51.42M | 47.84M | 62.56M |
| SG&A % of Revenue | 104.25% | 138.4% | 113.46% | 87.27% | 95.97% | 78.56% | 61.53% | 48.04% | 48.34% |
| Research & Development | 4.01M | 5.48M | 4.42M | 3.42M | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
| R&D % of Revenue | 18.9% | 17.36% | 9.55% | 5.76% | 5.68% | 6.7% | 5.93% | 6.04% | 4.89% |
| Other Operating Expenses | 746K | 75K | 125K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.38M▲ 0% | -33.17M▼ 102.6% | -31.3M▲ 5.6% | -19.85M▲ 36.6% | -27.07M▼ 36.4% | -18.63M▲ 31.2% | -5.6M▲ 69.9% | 7.73M▲ 238.0% | 14.3M▲ 85.0% |
| Operating Margin % | -77.25% | -105.12% | -67.62% | -33.5% | -40.14% | -25.85% | -6.7% | 7.76% | 11.05% |
| Operating Income Growth % | -463.71% | -102.55% | 5.64% | 36.57% | -36.36% | 31.19% | 69.94% | 237.99% | 85.04% |
| EBITDA | -15.66M | -32.33M | -29.78M | -18.34M | -25.45M | -16.74M | -3.89M | 9.21M | 15.75M |
| EBITDA Margin % | -73.87% | -102.45% | -64.33% | -30.95% | -37.73% | -23.24% | -4.66% | 9.25% | 12.17% |
| EBITDA Growth % | -530.06% | -106.44% | 7.9% | 38.41% | -38.74% | 34.2% | 76.74% | 336.52% | 70.97% |
| D&A (Non-Cash Add-back) | 716K | 842K | 1.52M | 1.51M | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| EBIT | -16.38M | -33.17M | -31.3M | -19.85M | -27.07M | -18.63M | -5.6M | 7.73M | 14.3M |
| Net Interest Income | -153K | -79K | -847K | -71K | -55K | 3K | 661K | 1.13M | 2.13M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 3K | 661K | 1.13M | 2.13M |
| Interest Expense | 153K | 79K | 847K | 71K | 55K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -153K | -144K | -847K | -71K | -55K | 2.09M | 661K | 1.13M | 3.9M |
| Pretax Income | -16.53M▲ 0% | -33.32M▼ 101.5% | -32.15M▲ 3.5% | -19.93M▲ 38.0% | -27.13M▼ 36.2% | -16.54M▲ 39.0% | -4.94M▲ 70.1% | 8.86M▲ 279.3% | 18.19M▲ 105.4% |
| Pretax Margin % | -77.97% | -105.57% | -69.45% | -33.62% | -40.22% | -22.96% | -5.91% | 8.89% | 14.06% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 305K | 810K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3.44% | 4.45% |
| Net Income | -11.38M▲ 0% | -33.32M▼ 192.8% | -32.15M▲ 3.5% | -19.93M▲ 38.0% | -27.13M▼ 36.2% | -16.54M▲ 39.0% | -4.94M▲ 70.1% | 8.55M▲ 273.1% | 17.38M▲ 103.3% |
| Net Margin % | -53.67% | -105.57% | -69.45% | -33.62% | -40.22% | -22.96% | -5.91% | 8.58% | 13.43% |
| Net Income Growth % | -288.57% | -192.81% | 3.51% | 38.02% | -36.15% | 39.03% | 70.15% | 273.15% | 103.3% |
| Net Income (Continuing) | -16.53M | -33.32M | -32.15M | -19.93M | -27.13M | -16.54M | -4.94M | 8.55M | 17.38M |
| Discontinued Operations | 5.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26▲ 0% | -0.61▼ 134.6% | -0.56▲ 8.2% | -0.33▲ 41.1% | -0.40▼ 21.2% | -0.24▲ 40.0% | -0.07▲ 72.5% | 0.11▲ 266.9% | 0.20▲ 81.8% |
| EPS Growth % | -231.21% | -134.62% | 8.2% | 41.07% | -21.21% | 40% | 72.54% | 266.92% | 81.82% |
| EPS (Basic) | -0.26 | -0.61 | -0.56 | -0.33 | -0.40 | -0.24 | -0.07 | 0.10 | 0.22 |
| Diluted Shares Outstanding | 44.6M | 55.01M | 57.06M | 61.07M | 67.19M | 69.73M | 74.98M | 79.72M | 85.44M |
| Basic Shares Outstanding | 44.6M | 55.01M | 57.06M | 61.07M | 67.19M | 68.92M | 70.54M | 85.42M | 79.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NAGE Balance Sheet
Niagen Bioscience Inc (NAGE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 57.18M | 36.53M | 33.52M | 32.22M | 48.91M | 46.57M | 49.53M | 64.1M | 96.81M |
| Cash & Short-Term Investments | 45.39M | 22.42M | 18.61M | 16.5M | 28.02M | 20.29M | 27.17M | 44.51M | 64.79M |
| Cash Only | 45.39M | 22.42M | 18.61M | 16.5M | 28.02M | 20.29M | 27.17M | 44.51M | 64.79M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 5.34M | 4.42M | 2.17M | 2.69M | 5.23M | 8.48M | 5.23M | 7.77M | 9.74M |
| Days Sales Outstanding | 91.9 | 51.07 | 17.15 | 16.59 | 28.28 | 42.97 | 22.86 | 28.47 | 27.47 |
| Inventory | 5.8M | 8.25M | 11.54M | 11.68M | 13.6M | 14.68M | 14.53M | 9.19M | 20.42M |
| Days Inventory Outstanding | 197.27 | 194.23 | 205.16 | 177.8 | 191.24 | 183.13 | 161.68 | 88.27 | 161.24 |
| Other Current Assets | 0 | 877K | 200K | 200K | 200K | 3.12M | 2.6M | 2.63M | 1.85M |
| Total Non-Current Assets | 5.54M | 5.7M | 6.73M | 6.14M | 8.94M | 7.49M | 5.43M | 4.18M | 9.6M |
| Property, Plant & Equipment | 2.87M | 3.58M | 4.66M | 4.43M | 7.36M | 6.32M | 4.54M | 3.45M | 3.52M |
| Fixed Asset Turnover | 7.38x | 8.80x | 9.94x | 13.37x | 9.17x | 11.40x | 18.42x | 28.88x | 36.82x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.65M | 1.55M | 1.31M | 1.08M | 857K | 671K | 510K | 359K | 5.66M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.02M | 566K | 762K | 625K | 723K | 497K | 383K | 368K | 425K |
| Total Assets | 62.72M▲ 0% | 42.23M▼ 32.7% | 40.25M▼ 4.7% | 38.36M▼ 4.7% | 57.84M▲ 50.8% | 54.06M▼ 6.5% | 54.96M▲ 1.7% | 68.28M▲ 24.2% | 106.41M▲ 55.8% |
| Asset Turnover | 0.34x | 0.75x | 1.15x | 1.54x | 1.17x | 1.33x | 1.52x | 1.46x | 1.22x |
| Asset Growth % | 217.56% | -32.67% | -4.7% | -4.69% | 50.79% | -6.54% | 1.68% | 24.22% | 55.84% |
| Total Current Liabilities | 8.09M | 14.44M | 15.06M | 16.48M | 17.61M | 17.87M | 20.62M | 17.95M | 19.92M |
| Accounts Payable | 3.72M | 9.55M | 9.63M | 9.45M | 10.42M | 9.68M | 10.23M | 8.53M | 10.8M |
| Days Payables Outstanding | 126.58 | 224.81 | 171.21 | 143.74 | 146.55 | 120.77 | 113.9 | 81.87 | 85.23 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M |
| Deferred Revenue (Current) | 314K | 275K | 169K | 278K | 161K | 157K | 195K | 611K | 0 |
| Other Current Liabilities | 114K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.12M |
| Current Ratio | 7.07x | 2.53x | 2.23x | 1.96x | 2.78x | 2.61x | 2.40x | 3.57x | 4.86x |
| Quick Ratio | 6.35x | 1.96x | 1.46x | 1.25x | 2.00x | 1.78x | 1.70x | 3.06x | 3.83x |
| Cash Conversion Cycle | 162.59 | 20.48 | 51.1 | 50.65 | 72.97 | 105.33 | 70.65 | 34.86 | 103.48 |
| Total Non-Current Liabilities | 802K | 614K | 4.74M | 5.46M | 8.5M | 7.52M | 5.89M | 4.24M | 9.95M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 310K | 137K | 866K | 1.02M | 4.15M | 3.56M | 2.58M | 1.66M | 1.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 492K | 477K | 0 | 0 | 0 | 0 | 0 | 0 | 5.46M |
| Total Liabilities | 8.89M | 15.05M | 19.8M | 21.93M | 26.11M | 25.39M | 26.51M | 22.18M | 29.87M |
| Total Debt | 506K | 310K | 1.72M | 1.64M | 4.7M | 4.26M | 3.28M | 2.65M | 2.82M |
| Net Debt | -44.88M | -22.11M | -16.89M | -14.86M | -23.32M | -16.03M | -23.9M | -41.86M | -61.97M |
| Debt / Equity | 0.01x | 0.01x | 0.08x | 0.10x | 0.15x | 0.15x | 0.12x | 0.06x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.29x | 0.18x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -4.54x | -3.94x |
| Interest Coverage | -107.04x | -419.90x | -36.95x | -279.63x | -492.24x | - | - | - | - |
| Total Equity | 53.83M▲ 0% | 27.18M▼ 49.5% | 20.45M▼ 24.8% | 16.42M▼ 19.7% | 31.73M▲ 93.2% | 28.67M▼ 9.6% | 28.46M▼ 0.8% | 46.09M▲ 62.0% | 76.53M▲ 66.0% |
| Equity Growth % | 439.72% | -49.52% | -24.77% | -19.67% | 93.17% | -9.63% | -0.75% | 61.98% | 66.04% |
| Book Value per Share | 1.21 | 0.49 | 0.36 | 0.27 | 0.47 | 0.41 | 0.38 | 0.58 | 0.90 |
| Total Shareholders' Equity | 53.83M | 27.18M | 20.45M | 16.42M | 31.73M | 28.67M | 28.46M | 46.09M | 76.53M |
| Common Stock | 55K | 55K | 60K | 62K | 68K | 74K | 75K | 77K | 79K |
| Retained Earnings | -56.6M | -89.75M | -121.9M | -141.82M | -168.95M | -185.49M | -190.46M | -181.91M | -164.53M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -3K | -2K | -3K | -4K | -4K | -9K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAGE Cash Flow Statement
Niagen Bioscience Inc (NAGE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.8M | -20.91M | -20.44M | -10.6M | -24.16M | -15.1M | 7.12M | 12.11M | 13.44M |
| Operating CF Margin % | -46.24% | -66.25% | -44.15% | -17.89% | -35.82% | -20.95% | 8.52% | 12.16% | 10.38% |
| Operating CF Growth % | -233.86% | -113.26% | 2.24% | 48.14% | -127.95% | 37.52% | 147.14% | 70.14% | 10.97% |
| Net Income | -11.38M | -33.32M | -32.15M | -19.93M | -27.13M | -16.54M | -4.94M | 8.55M | 17.38M |
| Depreciation & Amortization | 716K | 842K | 1.52M | 1.51M | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| Stock-Based Compensation | 4.61M | 6.37M | 7.17M | 6.94M | 6.2M | 5.74M | 4.75M | 3.66M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -5.75M | 4K | 2.59M | -204K | -124K | -167K | 977K | -4.71M | 2.9M |
| Working Capital Changes | 2M | 5.19M | 427K | 1.08M | -4.73M | -6.01M | 4.62M | 3.13M | -8.3M |
| Change in Receivables | 937K | 1.11M | -44K | -555K | -2.58M | -3.32M | 2.25M | -1.28M | -756K |
| Change in Inventory | 2.18M | -2.45M | -3.29M | -148K | -1.92M | -1.08M | 152K | 5.33M | -11.63M |
| Change in Payables | -2.36M | 5.83M | 78K | -181K | 978K | -744K | 553K | -1.07M | 2.27M |
| Cash from Investing | 4.6M | -1.77M | -249K | -165K | -409K | -334K | -143K | -143K | -292K |
| Capital Expenditures | -1.17M | -1.32M | -743K | -124K | -409K | -334K | -148K | -163K | -292K |
| CapEx % of Revenue | 5.5% | 4.19% | 1.61% | 0.21% | 0.61% | 0.46% | 0.18% | 0.16% | 0.23% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 5.77M | -454K | 494K | -41K | 0 | 0 | 5K | 20K | 0 |
| Cash from Financing | 48.95M | -90K | 16.88M | 8.65M | 36.09M | 7.65M | -90K | 5.37M | 6.98M |
| Debt Issued (Net) | -608K | -196K | 9.72M | -272K | -31K | -16K | -15K | -11K | -12K |
| Equity Issued (Net) | 46.59M | -404K | 6.77M | 4.86M | 26.74M | 7.75M | 0 | 5.43M | 7M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -404K | 0 | 0 | 0 | 0 | 0 | 0 | -251K |
| Other Financing | 2.96M | 510K | 388K | 4.07M | 9.38M | -77K | -75K | -52K | 0 |
| Net Change in Cash | 43.75M▲ 0% | -22.77M▼ 152.1% | -3.8M▲ 83.3% | -2.12M▲ 44.4% | 11.52M▲ 644.8% | -7.78M▼ 167.5% | 6.88M▲ 188.5% | 17.34M▲ 151.8% | 20.13M▲ 16.1% |
| Free Cash Flow | -11.15M▲ 0% | -22.36M▼ 100.4% | -21.19M▲ 5.2% | -10.74M▲ 49.3% | -24.57M▼ 128.7% | -15.43M▲ 37.2% | 6.97M▲ 145.2% | 11.95M▲ 71.4% | 13.14M▲ 10.0% |
| FCF Margin % | -52.62% | -70.86% | -45.78% | -18.13% | -36.43% | -21.42% | 8.34% | 11.99% | 10.16% |
| FCF Growth % | -139.3% | -100.45% | 5.22% | 49.31% | -128.75% | 37.2% | 145.16% | 71.42% | 10.04% |
| FCF per Share | -0.25 | -0.41 | -0.37 | -0.18 | -0.37 | -0.22 | 0.09 | 0.15 | 0.15 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.63x | 0.64x | 0.53x | 0.89x | 0.91x | -1.44x | 1.42x | 0.77x |
| Interest Paid | 57K | 41K | 33K | 13K | 1K | 1K | 2K | 1K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAGE Key Ratios
Niagen Bioscience Inc (NAGE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -38.4% | -35.66% | -82.25% | -135.01% | -108.09% | -112.68% | -54.77% | -17.29% | 22.94% | 28.35% |
| Return on Invested Capital (ROIC) | -30.7% | -137.38% | -354.83% | -544.41% | -582.11% | -407.15% | -132.74% | -48.83% | 131.74% | 114.07% |
| Gross Margin | 47.96% | 49.42% | 50.88% | 55.67% | 59.53% | 61.51% | 59.4% | 60.76% | 61.84% | 64.28% |
| Net Margin | -13.52% | -53.67% | -105.57% | -69.45% | -33.62% | -40.22% | -22.96% | -5.91% | 8.58% | 13.43% |
| Debt / Equity | 0.06x | 0.01x | 0.01x | 0.08x | 0.10x | 0.15x | 0.15x | 0.12x | 0.06x | 0.04x |
| Interest Coverage | -7.81x | -107.04x | -419.90x | -36.95x | -279.63x | -492.24x | - | - | - | - |
| FCF Conversion | 1.00x | 0.86x | 0.63x | 0.64x | 0.53x | 0.89x | 0.91x | -1.44x | 1.42x | 0.77x |
| Revenue Growth | 21.13% | -2.14% | 48.85% | 46.69% | 28.01% | 13.82% | 6.82% | 15.99% | 19.18% | 29.95% |
NAGE Frequently Asked Questions
Niagen Bioscience Inc (NAGE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Niagen Bioscience Inc (NAGE) reported $129.4M in revenue for fiscal year 2025.
Niagen Bioscience Inc (NAGE) grew revenue by 29.9% over the past year. This is strong growth.
Yes, Niagen Bioscience Inc (NAGE) is profitable, generating $17.4M in net income for fiscal year 2025 (13.4% net margin).
Dividend & Returns
Niagen Bioscience Inc (NAGE) has a return on equity (ROE) of 28.3%. This is excellent, indicating efficient use of shareholder capital.
Niagen Bioscience Inc (NAGE) generated $13.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More NAGE
Niagen Bioscience Inc (NAGE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates